Back to Search
Start Over
COVID‐19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment
- Source :
- Cancer Medicine
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Background There is limited data on outcomes in cancer patients with coronavirus disease 2019 (COVID‐19) from lower middle‐income countries (LMICs). Patients and Methods This was an observational study, conducted between 12 April and 10 June 2020 at Tata Memorial centre, Mumbai, in cancer patients undergoing systemic therapy with laboratory confirmed COVID‐19. The objectives were to evaluate cumulative 30‐day all‐cause mortality, COVID‐19 attributable mortality, factors predicting mortality, and time to viral negativity after initial diagnosis. Results Of the 24 660 footfalls and 7043 patients evaluated, 230 patients on active systemic therapy with a median age of 42 (1‐75) years were included. COVID‐19 infection severity, as per WHO criteria, was mild, moderate, and severe in 195 (85%), 11 (5%), and 24 (11%) patients, respectively. Twenty‐three patients (10%) expired during follow‐up, with COVID‐19 attributable mortality seen in 15 patients (6.5%). There were no mortalities in the pediatric cohort of 31 (14%) patients. Advanced stage cancer being treated with palliative intent vs others [30‐day mortality 24%% vs 5%, odds ratio (OR) 5.6, 95% CI 2.28‐13.78, P<br />COVID‐19 attributable mortality in cancer patients on systemic therapy in LMICs appears lower than published data and slightly more than an unselected patient's cohort. Delayed recovery in terms of SARS COV‐2 negativity is seen in these patients. Treating Cancer remains the priority.
- Subjects :
- Male
0301 basic medicine
Cancer Research
Comorbidity
LMICs
systemic therapy
0302 clinical medicine
Interquartile range
Neoplasms
Outcome Assessment, Health Care
Medicine
Prospective Studies
Young adult
Child
Prospective cohort study
Original Research
Mortality rate
Middle Aged
Survival Rate
Oncology
Radiology Nuclear Medicine and imaging
Child, Preschool
030220 oncology & carcinogenesis
Cohort
Female
Adult
medicine.medical_specialty
Adolescent
India
Antiviral Agents
Young Adult
03 medical and health sciences
COVID‐19
Internal medicine
cancer
Humans
Radiology, Nuclear Medicine and imaging
Pandemics
Survival rate
Aged
SARS-CoV-2
business.industry
Clinical Cancer Research
COVID-19
Infant
Cancer
medicine.disease
Pediatric cancer
030104 developmental biology
RT‐PCR negativity
business
Subjects
Details
- ISSN :
- 20457634
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....f2bd7a4be8b2189bd0bd652e232b119b
- Full Text :
- https://doi.org/10.1002/cam4.3423